Tokyo, April 1 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000060925) titled 'Efficacy and safety of imeglimin in Japanese patients with type 2 diabetes' on April 1.
Study Type:
Observational
Primary Sponsor:
Institute - Juntendo university
Condition:
Condition - Type 2 diabetes
Classification by malignancy - Others
Genomic information - NO
Objective:
Narrative objectives1 - To examine efficacy and safety of imeglimin in Japanese patients with type 2 diabetes in real world clinical state
Basic objectives2 - Efficacy
Eligibility:
Age-lower limit - 18
years-old
=
Gender - Male and Female
Key inclusion criteria - Type 2 diabetes
Key exclusion criteria - Type 1 diabetes
Target Size - 300
Recruitment Status:
Recruitment status - Open public recruiting
Date of protocol fixation - 2026 Year 02 Month 04 Day
Date of IRB - 2026 Year 03 Month 06 Day
Anticipated trial start date - 2026 Year 03 Month 06 Day
Last follow-up date - 2026 Year 08 Month 31 Day
To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000069659
Disclaimer: Curated by HT Syndication.
